NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 107 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.50 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40 | -88.7% | 37,390 | -72.8% | 0.00% | -86.7% |
| Q2 2023 | $355 | -42.8% | 137,250 | -9.9% | 0.02% | -48.3% |
| Q1 2023 | $621 | +67.4% | 152,260 | +106.1% | 0.03% | +38.1% |
| Q4 2022 | $371 | -100.0% | 73,890 | -5.1% | 0.02% | -66.1% |
| Q3 2022 | $1,018,000 | +10.3% | 77,840 | +8.2% | 0.06% | -10.1% |
| Q2 2022 | $923,000 | +109.3% | 71,963 | +148.9% | 0.07% | +137.9% |
| Q1 2022 | $441,000 | +20.5% | 28,913 | +40.0% | 0.03% | -37.0% |
| Q4 2021 | $366,000 | – | 20,646 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |